Global Parkinsons Disease Drug Market Insights, Forecast to 2029

Publisher Name :
Date: 02-Aug-2023
No. of pages: 113
Inquire Before Buying

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.

The global Parkinsons Disease Drug market is projected to grow from US$ 5763.6 million in 2023 to US$ 7419.9 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period.

Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.

Report Includes:

This report presents an overview of global market for Parkinsons Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.

This report researches the key producers of Parkinsons Disease Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Parkinsons Disease Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Parkinsons Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global Parkinsons Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for Parkinsons Disease Drug sales, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories, Lundbeck and Sun Pharma, etc.

By Company

- Teva

- Novartis AG

- GSK

- AbbVie

- Merck

- Boehringer Ingelheim

- Impax Laboratories

- Lundbeck

- Sun Pharma

- Wockhardt

- UCB

- Bausch Health

- Acadia

Segment by Type

- Carbidopa/Levodopa

- Dopamine Receptor Agonists

- MAO-Inhibitors

Segment by Application

- Hospital

- Clinics

- Other

Segment by Region

- US & Canada

- - U.S.

- - Canada

- China

- Asia (excluding China)

- - Japan

- - South Korea

- - China Taiwan

- Southeast Asia

- - India

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Middle East, Africa, Latin America

- - Brazil

- - Mexico

- - Turkey

- - Israel

- - GCC Countries

Chapter Outline

Chapter 1: Introduces the Report Scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Sales (consumption), revenue of Parkinsons Disease Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 3: Detailed analysis of Parkinsons Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.

Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.

Chapter 8: China by type, by application sales and revenue for each segment.

Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.

Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Parkinsons Disease Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 14: The main points and conclusions of the report.

Global Parkinsons Disease Drug Market Insights, Forecast to 2029

Table of Contents
1 Study Coverage
1.1 Parkinsons Disease Drug Product Introduction
1.2 Market by Type
1.2.1 Global Parkinsons Disease Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Carbidopa/Levodopa
1.2.3 Dopamine Receptor Agonists
1.2.4 MAO-Inhibitors
1.3 Market by Application
1.3.1 Global Parkinsons Disease Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Parkinsons Disease Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Parkinsons Disease Drug Revenue by Region
2.2.1 Global Parkinsons Disease Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Parkinsons Disease Drug Revenue by Region (2018-2023)
2.2.3 Global Parkinsons Disease Drug Revenue by Region (2024-2029)
2.2.4 Global Parkinsons Disease Drug Revenue Market Share by Region (2018-2029)
2.3 Global Parkinsons Disease Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Parkinsons Disease Drug Sales by Region
2.4.1 Global Parkinsons Disease Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Parkinsons Disease Drug Sales by Region (2018-2023)
2.4.3 Global Parkinsons Disease Drug Sales by Region (2024-2029)
2.4.4 Global Parkinsons Disease Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Parkinsons Disease Drug Sales by Manufacturers
3.1.1 Global Parkinsons Disease Drug Sales by Manufacturers (2018-2023)
3.1.2 Global Parkinsons Disease Drug Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Parkinsons Disease Drug in 2022
3.2 Global Parkinsons Disease Drug Revenue by Manufacturers
3.2.1 Global Parkinsons Disease Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Parkinsons Disease Drug Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Parkinsons Disease Drug Revenue in 2022
3.3 Global Key Players of Parkinsons Disease Drug, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Parkinsons Disease Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Parkinsons Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Parkinsons Disease Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Parkinsons Disease Drug, Product Offered and Application
3.8 Global Key Manufacturers of Parkinsons Disease Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Parkinsons Disease Drug Sales by Type
4.1.1 Global Parkinsons Disease Drug Historical Sales by Type (2018-2023)
4.1.2 Global Parkinsons Disease Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Parkinsons Disease Drug Sales Market Share by Type (2018-2029)
4.2 Global Parkinsons Disease Drug Revenue by Type
4.2.1 Global Parkinsons Disease Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Parkinsons Disease Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Parkinsons Disease Drug Revenue Market Share by Type (2018-2029)
4.3 Global Parkinsons Disease Drug Price by Type
4.3.1 Global Parkinsons Disease Drug Price by Type (2018-2023)
4.3.2 Global Parkinsons Disease Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Parkinsons Disease Drug Sales by Application
5.1.1 Global Parkinsons Disease Drug Historical Sales by Application (2018-2023)
5.1.2 Global Parkinsons Disease Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Parkinsons Disease Drug Sales Market Share by Application (2018-2029)
5.2 Global Parkinsons Disease Drug Revenue by Application
5.2.1 Global Parkinsons Disease Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Parkinsons Disease Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Parkinsons Disease Drug Revenue Market Share by Application (2018-2029)
5.3 Global Parkinsons Disease Drug Price by Application
5.3.1 Global Parkinsons Disease Drug Price by Application (2018-2023)
5.3.2 Global Parkinsons Disease Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Parkinsons Disease Drug Market Size by Type
6.1.1 US & Canada Parkinsons Disease Drug Sales by Type (2018-2029)
6.1.2 US & Canada Parkinsons Disease Drug Revenue by Type (2018-2029)
6.2 US & Canada Parkinsons Disease Drug Market Size by Application
6.2.1 US & Canada Parkinsons Disease Drug Sales by Application (2018-2029)
6.2.2 US & Canada Parkinsons Disease Drug Revenue by Application (2018-2029)
6.3 US & Canada Parkinsons Disease Drug Market Size by Country
6.3.1 US & Canada Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Parkinsons Disease Drug Sales by Country (2018-2029)
6.3.3 US & Canada Parkinsons Disease Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Parkinsons Disease Drug Market Size by Type
7.1.1 Europe Parkinsons Disease Drug Sales by Type (2018-2029)
7.1.2 Europe Parkinsons Disease Drug Revenue by Type (2018-2029)
7.2 Europe Parkinsons Disease Drug Market Size by Application
7.2.1 Europe Parkinsons Disease Drug Sales by Application (2018-2029)
7.2.2 Europe Parkinsons Disease Drug Revenue by Application (2018-2029)
7.3 Europe Parkinsons Disease Drug Market Size by Country
7.3.1 Europe Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Parkinsons Disease Drug Sales by Country (2018-2029)
7.3.3 Europe Parkinsons Disease Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Parkinsons Disease Drug Market Size
8.1.1 China Parkinsons Disease Drug Sales (2018-2029)
8.1.2 China Parkinsons Disease Drug Revenue (2018-2029)
8.2 China Parkinsons Disease Drug Market Size by Application
8.2.1 China Parkinsons Disease Drug Sales by Application (2018-2029)
8.2.2 China Parkinsons Disease Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Parkinsons Disease Drug Market Size by Type
9.1.1 Asia Parkinsons Disease Drug Sales by Type (2018-2029)
9.1.2 Asia Parkinsons Disease Drug Revenue by Type (2018-2029)
9.2 Asia Parkinsons Disease Drug Market Size by Application
9.2.1 Asia Parkinsons Disease Drug Sales by Application (2018-2029)
9.2.2 Asia Parkinsons Disease Drug Revenue by Application (2018-2029)
9.3 Asia Parkinsons Disease Drug Sales by Region
9.3.1 Asia Parkinsons Disease Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Parkinsons Disease Drug Revenue by Region (2018-2029)
9.3.3 Asia Parkinsons Disease Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Parkinsons Disease Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Parkinsons Disease Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Teva
11.1.1 Teva Company Information
11.1.2 Teva Overview
11.1.3 Teva Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Teva Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Teva Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Information
11.2.2 Novartis AG Overview
11.2.3 Novartis AG Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Novartis AG Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis AG Recent Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Overview
11.3.3 GSK Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 GSK Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GSK Recent Developments
11.4 AbbVie
11.4.1 AbbVie Company Information
11.4.2 AbbVie Overview
11.4.3 AbbVie Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 AbbVie Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AbbVie Recent Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Overview
11.5.3 Merck Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Merck Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merck Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Information
11.6.2 Boehringer Ingelheim Overview
11.6.3 Boehringer Ingelheim Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Boehringer Ingelheim Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Boehringer Ingelheim Recent Developments
11.7 Impax Laboratories
11.7.1 Impax Laboratories Company Information
11.7.2 Impax Laboratories Overview
11.7.3 Impax Laboratories Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 Impax Laboratories Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Impax Laboratories Recent Developments
11.8 Lundbeck
11.8.1 Lundbeck Company Information
11.8.2 Lundbeck Overview
11.8.3 Lundbeck Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Lundbeck Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Lundbeck Recent Developments
11.9 Sun Pharma
11.9.1 Sun Pharma Company Information
11.9.2 Sun Pharma Overview
11.9.3 Sun Pharma Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Sun Pharma Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Sun Pharma Recent Developments
11.10 Wockhardt
11.10.1 Wockhardt Company Information
11.10.2 Wockhardt Overview
11.10.3 Wockhardt Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Wockhardt Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Wockhardt Recent Developments
11.11 UCB
11.11.1 UCB Company Information
11.11.2 UCB Overview
11.11.3 UCB Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 UCB Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 UCB Recent Developments
11.12 Bausch Health
11.12.1 Bausch Health Company Information
11.12.2 Bausch Health Overview
11.12.3 Bausch Health Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Bausch Health Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Bausch Health Recent Developments
11.13 Acadia
11.13.1 Acadia Company Information
11.13.2 Acadia Overview
11.13.3 Acadia Parkinsons Disease Drug Sales, Price, Revenue and Gross Margin (2018-2023)
11.13.4 Acadia Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Acadia Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Parkinsons Disease Drug Industry Chain Analysis
12.2 Parkinsons Disease Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Parkinsons Disease Drug Production Mode & Process
12.4 Parkinsons Disease Drug Sales and Marketing
12.4.1 Parkinsons Disease Drug Sales Channels
12.4.2 Parkinsons Disease Drug Distributors
12.5 Parkinsons Disease Drug Customers
13 Market Dynamics
13.1 Parkinsons Disease Drug Industry Trends
13.2 Parkinsons Disease Drug Market Drivers
13.3 Parkinsons Disease Drug Market Challenges
13.4 Parkinsons Disease Drug Market Restraints
14 Key Findings in The Global Parkinsons Disease Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Parkinsons Disease Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Carbidopa/Levodopa
Table 3. Major Manufacturers of Dopamine Receptor Agonists
Table 4. Major Manufacturers of MAO-Inhibitors
Table 5. Global Parkinsons Disease Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Parkinsons Disease Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Parkinsons Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Parkinsons Disease Drug Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Parkinsons Disease Drug Revenue Market Share by Region (2018-2023)
Table 10. Global Parkinsons Disease Drug Revenue Market Share by Region (2024-2029)
Table 11. Global Parkinsons Disease Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Parkinsons Disease Drug Sales by Region (2018-2023) & (K Doses)
Table 13. Global Parkinsons Disease Drug Sales by Region (2024-2029) & (K Doses)
Table 14. Global Parkinsons Disease Drug Sales Market Share by Region (2018-2023)
Table 15. Global Parkinsons Disease Drug Sales Market Share by Region (2024-2029)
Table 16. Global Parkinsons Disease Drug Sales by Manufacturers (2018-2023) & (K Doses)
Table 17. Global Parkinsons Disease Drug Sales Share by Manufacturers (2018-2023)
Table 18. Global Parkinsons Disease Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Parkinsons Disease Drug Revenue Share by Manufacturers (2018-2023)
Table 20. Global Key Players of Parkinsons Disease Drug, Industry Ranking, 2021 VS 2022 VS 2023
Table 21. Parkinsons Disease Drug Price by Manufacturers 2018-2023 (USD/Dose)
Table 22. Global Parkinsons Disease Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Parkinsons Disease Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinsons Disease Drug as of 2022)
Table 24. Global Key Manufacturers of Parkinsons Disease Drug, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Parkinsons Disease Drug, Product Offered and Application
Table 26. Global Key Manufacturers of Parkinsons Disease Drug, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Parkinsons Disease Drug Sales by Type (2018-2023) & (K Doses)
Table 29. Global Parkinsons Disease Drug Sales by Type (2024-2029) & (K Doses)
Table 30. Global Parkinsons Disease Drug Sales Share by Type (2018-2023)
Table 31. Global Parkinsons Disease Drug Sales Share by Type (2024-2029)
Table 32. Global Parkinsons Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Parkinsons Disease Drug Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Parkinsons Disease Drug Revenue Share by Type (2018-2023)
Table 35. Global Parkinsons Disease Drug Revenue Share by Type (2024-2029)
Table 36. Parkinsons Disease Drug Price by Type (2018-2023) & (USD/Dose)
Table 37. Global Parkinsons Disease Drug Price Forecast by Type (2024-2029) & (USD/Dose)
Table 38. Global Parkinsons Disease Drug Sales by Application (2018-2023) & (K Doses)
Table 39. Global Parkinsons Disease Drug Sales by Application (2024-2029) & (K Doses)
Table 40. Global Parkinsons Disease Drug Sales Share by Application (2018-2023)
Table 41. Global Parkinsons Disease Drug Sales Share by Application (2024-2029)
Table 42. Global Parkinsons Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Parkinsons Disease Drug Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Parkinsons Disease Drug Revenue Share by Application (2018-2023)
Table 45. Global Parkinsons Disease Drug Revenue Share by Application (2024-2029)
Table 46. Parkinsons Disease Drug Price by Application (2018-2023) & (USD/Dose)
Table 47. Global Parkinsons Disease Drug Price Forecast by Application (2024-2029) & (USD/Dose)
Table 48. US & Canada Parkinsons Disease Drug Sales by Type (2018-2023) & (K Doses)
Table 49. US & Canada Parkinsons Disease Drug Sales by Type (2024-2029) & (K Doses)
Table 50. US & Canada Parkinsons Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 51. US & Canada Parkinsons Disease Drug Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Parkinsons Disease Drug Sales by Application (2018-2023) & (K Doses)
Table 53. US & Canada Parkinsons Disease Drug Sales by Application (2024-2029) & (K Doses)
Table 54. US & Canada Parkinsons Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 55. US & Canada Parkinsons Disease Drug Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Parkinsons Disease Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Parkinsons Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 58. US & Canada Parkinsons Disease Drug Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Parkinsons Disease Drug Sales by Country (2018-2023) & (K Doses)
Table 60. US & Canada Parkinsons Disease Drug Sales by Country (2024-2029) & (K Doses)
Table 61. Europe Parkinsons Disease Drug Sales by Type (2018-2023) & (K Doses)
Table 62. Europe Parkinsons Disease Drug Sales by Type (2024-2029) & (K Doses)
Table 63. Europe Parkinsons Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 64. Europe Parkinsons Disease Drug Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Parkinsons Disease Drug Sales by Application (2018-2023) & (K Doses)
Table 66. Europe Parkinsons Disease Drug Sales by Application (2024-2029) & (K Doses)
Table 67. Europe Parkinsons Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 68. Europe Parkinsons Disease Drug Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Parkinsons Disease Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Parkinsons Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 71. Europe Parkinsons Disease Drug Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Parkinsons Disease Drug Sales by Country (2018-2023) & (K Doses)
Table 73. Europe Parkinsons Disease Drug Sales by Country (2024-2029) & (K Doses)
Table 74. China Parkinsons Disease Drug Sales by Type (2018-2023) & (K Doses)
Table 75. China Parkinsons Disease Drug Sales by Type (2024-2029) & (K Doses)
Table 76. China Parkinsons Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 77. China Parkinsons Disease Drug Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Parkinsons Disease Drug Sales by Application (2018-2023) & (K Doses)
Table 79. China Parkinsons Disease Drug Sales by Application (2024-2029) & (K Doses)
Table 80. China Parkinsons Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 81. China Parkinsons Disease Drug Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Parkinsons Disease Drug Sales by Type (2018-2023) & (K Doses)
Table 83. Asia Parkinsons Disease Drug Sales by Type (2024-2029) & (K Doses)
Table 84. Asia Parkinsons Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 85. Asia Parkinsons Disease Drug Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Parkinsons Disease Drug Sales by Application (2018-2023) & (K Doses)
Table 87. Asia Parkinsons Disease Drug Sales by Application (2024-2029) & (K Doses)
Table 88. Asia Parkinsons Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 89. Asia Parkinsons Disease Drug Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Parkinsons Disease Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Parkinsons Disease Drug Revenue by Region (2018-2023) & (US$ Million)
Table 92. Asia Parkinsons Disease Drug Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Parkinsons Disease Drug Sales by Region (2018-2023) & (K Doses)
Table 94. Asia Parkinsons Disease Drug Sales by Region (2024-2029) & (K Doses)
Table 95. Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Type (2018-2023) & (K Doses)
Table 96. Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Type (2024-2029) & (K Doses)
Table 97. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Type (2018-2023) & (US$ Million)
Table 98. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Application (2018-2023) & (K Doses)
Table 100. Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Application (2024-2029) & (K Doses)
Table 101. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Application (2018-2023) & (US$ Million)
Table 102. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Parkinsons Disease Drug Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Country (2018-2023) & (K Doses)
Table 107. Middle East, Africa and Latin America Parkinsons Disease Drug Sales by Country (2024-2029) & (K Doses)
Table 108. Teva Company Information
Table 109. Teva Description and Major Businesses
Table 110. Teva Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 111. Teva Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Teva Recent Developments
Table 113. Novartis AG Company Information
Table 114. Novartis AG Description and Major Businesses
Table 115. Novartis AG Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 116. Novartis AG Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Novartis AG Recent Developments
Table 118. GSK Company Information
Table 119. GSK Description and Major Businesses
Table 120. GSK Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 121. GSK Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. GSK Recent Developments
Table 123. AbbVie Company Information
Table 124. AbbVie Description and Major Businesses
Table 125. AbbVie Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 126. AbbVie Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. AbbVie Recent Developments
Table 128. Merck Company Information
Table 129. Merck Description and Major Businesses
Table 130. Merck Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 131. Merck Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Merck Recent Developments
Table 133. Boehringer Ingelheim Company Information
Table 134. Boehringer Ingelheim Description and Major Businesses
Table 135. Boehringer Ingelheim Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 136. Boehringer Ingelheim Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Boehringer Ingelheim Recent Developments
Table 138. Impax Laboratories Company Information
Table 139. Impax Laboratories Description and Major Businesses
Table 140. Impax Laboratories Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 141. Impax Laboratories Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Impax Laboratories Recent Developments
Table 143. Lundbeck Company Information
Table 144. Lundbeck Description and Major Businesses
Table 145. Lundbeck Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 146. Lundbeck Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Lundbeck Recent Developments
Table 148. Sun Pharma Company Information
Table 149. Sun Pharma Description and Major Businesses
Table 150. Sun Pharma Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 151. Sun Pharma Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Sun Pharma Recent Developments
Table 153. Wockhardt Company Information
Table 154. Wockhardt Description and Major Businesses
Table 155. Wockhardt Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 156. Wockhardt Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Wockhardt Recent Developments
Table 158. UCB Company Information
Table 159. UCB Description and Major Businesses
Table 160. UCB Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 161. UCB Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. UCB Recent Developments
Table 163. Bausch Health Company Information
Table 164. Bausch Health Description and Major Businesses
Table 165. Bausch Health Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 166. Bausch Health Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Bausch Health Recent Developments
Table 168. Acadia Company Information
Table 169. Acadia Description and Major Businesses
Table 170. Acadia Parkinsons Disease Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 171. Acadia Parkinsons Disease Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Acadia Recent Developments
Table 173. Key Raw Materials Lists
Table 174. Raw Materials Key Suppliers Lists
Table 175. Parkinsons Disease Drug Distributors List
Table 176. Parkinsons Disease Drug Customers List
Table 177. Parkinsons Disease Drug Market Trends
Table 178. Parkinsons Disease Drug Market Drivers
Table 179. Parkinsons Disease Drug Market Challenges
Table 180. Parkinsons Disease Drug Market Restraints
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
List of Figures
Figure 1. Parkinsons Disease Drug Product Picture
Figure 2. Global Parkinsons Disease Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Parkinsons Disease Drug Market Share by Type in 2022 & 2029
Figure 4. Carbidopa/Levodopa Product Picture
Figure 5. Dopamine Receptor Agonists Product Picture
Figure 6. MAO-Inhibitors Product Picture
Figure 7. Global Parkinsons Disease Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Parkinsons Disease Drug Market Share by Application in 2022 & 2029
Figure 9. Hospital
Figure 10. Clinics
Figure 11. Other
Figure 12. Parkinsons Disease Drug Report Years Considered
Figure 13. Global Parkinsons Disease Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Parkinsons Disease Drug Revenue 2018-2029 (US$ Million)
Figure 15. Global Parkinsons Disease Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Parkinsons Disease Drug Revenue Market Share by Region (2018-2029)
Figure 17. Global Parkinsons Disease Drug Sales 2018-2029 ((K Doses)
Figure 18. Global Parkinsons Disease Drug Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Parkinsons Disease Drug Sales YoY (2018-2029) & (K Doses)
Figure 20. US & Canada Parkinsons Disease Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Parkinsons Disease Drug Sales YoY (2018-2029) & (K Doses)
Figure 22. Europe Parkinsons Disease Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Parkinsons Disease Drug Sales YoY (2018-2029) & (K Doses)
Figure 24. China Parkinsons Disease Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Parkinsons Disease Drug Sales YoY (2018-2029) & (K Doses)
  • Global Parkinson's Disease Therapeutics Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 99
    Parkinson's disease (PD), or simply Parkinson's, is a chronic degenerative disorder of The central nervous system that affects both The motor system and non-motor systems. The symptoms usually emerge slowly, and as The disease worsens, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson's disease dementia becomes common in advanced st......
  • Global Amantadine Hydrochloride Market Insights, Forecast to 2029
    Published: 29-Aug-2023        Price: US 4900 Onwards        Pages: 109
    Amantadine hydrochloride (CAS 665-66-7), C10H18ClN, the formula weight is 187.71, and its form is white crystal powder. The global Amantadine Hydrochloride market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period. Amantadine hydrochloride is clinically effective in preventing and treating infections of various influenza A viruses. In the influenza epidemic period, this product is use......
  • Global Rasagiline Tablet Market Insights, Forecast to 2029
    Published: 11-Aug-2023        Price: US 4900 Onwards        Pages: 107
    Rasagiline (Azilect, Azipron) is an irreversible inhibitor of monoamine oxidase-B used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The global Rasagiline Tablet market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period. The racemic form of the drug was invented by Aspro Nicholas in the early 1970s. Moussa B.H. Youdim identifi......
  • Global Parkinsons Disease Drug Market Insights, Forecast to 2029
    Published: 02-Aug-2023        Price: US 4900 Onwards        Pages: 113
    Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement. The global Parkinsons Disease Drug market is projected to grow from US$ 5763.6 million in 2023 to US$ 7419.9 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period. Global P......
  • Global Rasagiline Tablet Market Research Report 2023, Forecast to 2028
    Published: 20-Mar-2023        Price: US 2680 Onwards        Pages: 137
    Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data fo......
  • Global Rasagiline Tablet Professional Survey Report 2023, Forecast to 2028
    Published: 20-Mar-2023        Price: US 3280 Onwards        Pages: 109
    Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data fo......
  • Global Amantadine Hydrochloride Market Research Report 2023
    Published: 09-Mar-2023        Price: US 2900 Onwards        Pages: 98
    Amantadine hydrochloride (CAS 665-66-7), C10H18ClN, the formula weight is 187.71, and its form is white crystal powder. Highlights The global Amantadine Hydrochloride market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes. Amantadine hydrochloride is clinically effective......
  • Global Parkinson's Disease (PD) Drugs Professional Survey Report 2023, Forecast to 2028
    Published: 21-Feb-2023        Price: US 3280 Onwards        Pages: 133
    Levodopa, the most effective Parkinson's disease medication, is a natural chemical that passes into your brain and is converted to dopamine. Levodopa is combined with carbidopa (Lodosyn), which protects levodopa from early conversion to dopamine outside your brain. This prevents or lessens side effects such as nausea. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market v......
  • Global Parkinson's Disease (PD) Drugs Market Research Report 2023, Forecast to 2028
    Published: 21-Feb-2023        Price: US 2680 Onwards        Pages: 159
    Levodopa, the most effective Parkinson's disease medication, is a natural chemical that passes into your brain and is converted to dopamine. Levodopa is combined with carbidopa (Lodosyn), which protects levodopa from early conversion to dopamine outside your brain. This prevents or lessens side effects such as nausea. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market v......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs